Associated Papers
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN et al.
Nature Communications, 2026
41484121 (PubMed )
Supplement: 41467_2025_68076_MOESM1_ESM.pdf
Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma.
Jutten E et al.
Molecular Diagnosis & Therapy, 2025
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
37922692 (PubMed )
Supplement: mmc1.docx
Assessment of the Mutation Profile of Tonsillar Squamous Cell Carcinomas Using Targeted Next-Generation Sequencing.
Park HY et al.
Biomedicines, 2023
Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients.
Peng P et al.
Annals of Translational Medicine, 2021
Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma.
Broit N et al.
Molecular Cancer Research : Mcr, 2021
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Mack PC et al.
Cancer, 2020
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Pozdeyev N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.
McGranahan N et al.
Science Translational Medicine, 2015
Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.
Millis SZ et al.
Clinical Genitourinary Cancer, 2015
Select a paper to view details